{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:40:10Z","timestamp":1773967210320,"version":"3.50.1"},"reference-count":34,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T00:00:00Z","timestamp":1707609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess treatment adherence, effectiveness and safety outcomes of patients with chronic lymphocytic leukaemia (CLL) receiving ibrutinib in a real\u2010world setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients enrolled in REALITY were \u226518\u2009years with a confirmed diagnosis of CLL and were receiving ibrutinib as a first\u2010line (1L), 2L or \u22653L therapy. Treatment retention, adherence, progression\u2010free survival (PFS), overall survival (OS) and time to next therapy were assessed at 1 and 2\u2009years overall, by typology and by cytogenetic subgroups. PFS and OS were analysed using Kaplan\u2013Meier methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Exactly 302 patients were enrolled across 57 sites in Germany, from January 2017 to July 2021. One\u2010year retention rates were 69.9% overall (primary endpoint), 77.9% for 1L patients, and 77.6%\/78.8% for high\u2010risk patients with del17p\/<jats:italic>TP53<\/jats:italic>. At 2\u2009years, PFS\/OS rates were 77.8%\/90.7% overall (1L, 82.7%\/90.4%), and were consistent across cytogenetic subgroups. PFS rates were higher for 1L versus \u22653L patients. Patients with the low\u2010acceptance\/low\u2010control typology at baseline were less likely to retain treatment at 1\u2009year versus the high\u2010acceptance\/high\u2010control typology. No new safety signals were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The REALITY study provides further evidence of the effectiveness and safety of ibrutinib in patients with CLL in a real\u2010world setting, particularly in earlier treatment lines.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.14186","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T04:25:11Z","timestamp":1707711911000},"page":"927-937","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre <scp>REALITY<\/scp> study"],"prefix":"10.1111","volume":"112","author":[{"given":"Anke","family":"Gerhardt","sequence":"first","affiliation":[{"name":"Schwerpunktpraxis f\u00fcr H\u00e4matologie und Onkologie Potsdam  Potsdam Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"D\u00f6rfel","sequence":"additional","affiliation":[{"name":"Onkozentrum Dresden  Dresden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Schulz","sequence":"additional","affiliation":[{"name":"Praxis Internistischer Onkologie und H\u00e4matologie  Frechen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf","family":"Schlag","sequence":"additional","affiliation":[{"name":"H\u00e4matologisch\u2010Onkologische Schwerpunktpraxis W\u00fcrzburg  W\u00fcrzburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Vornholz","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag GmbH  Neuss Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Nejad\u2010Asgari","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag GmbH  Neuss Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Welslau","sequence":"additional","affiliation":[{"name":"MVZ am Klinikum Aschaffenburg  Aschaffenburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,2,11]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12427"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3702"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1239717"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3505"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2225"},{"key":"e_1_2_10_9_1","unstructured":"ecancer.European Commission Approves Ibrutinib in Two Forms of Blood Cancer. Accessed 15 January 2024.https:\/\/ecancer.org\/en\/news\/6483-european-commission-approves-ibrutinib-in-two-forms-of-blood-cancer"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006434"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_2_10_12_1","doi-asserted-by":"crossref","unstructured":"GhiaP OwenC BarrientosJ et al.Initiating first\u2010line (1L) ibrutinib (Ibr) in patients (pts) with chronic lymphocytic leukemia (CLL) improves overall survival (OS) outcomes to rates approximating an age\u2010matched population of \u226565\u2009years. Poster Presented at American Society of Hematology (ASH) Annual Meeting & Exposition San Diego CA USA; 10\u201313 December 2022: poster number 1809.","DOI":"10.1182\/blood-2022-163257"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279012"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014488"},{"key":"e_1_2_10_17_1","doi-asserted-by":"crossref","unstructured":"GhiaP WierdaW BarrP et al.Relapse after first\u2010line fixed duration ibrutinib + venetoclax: high response rates to ibrutinib retreatment and absence of btk mutations in patients with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) with up to 5\u2009years of follow\u2010up in the phase 2 CAPTIVATE study. Oral presented at American Society of Hematology (ASH) Annual Meeting; 9\u201312 December 2023 San Franscisco USA: 633.","DOI":"10.1182\/blood-2023-187128"},{"key":"e_1_2_10_18_1","unstructured":"Johnson & Johnson.New data from Phase 3 GLOW study show fixed\u2010duration treatment with IMBRUVICA\u00ae (ibrutinib) plus venetoclax demonstrated deeper and sustained undetectable minimal residual disease outcomes in first\u2010line chronic lymphocytic leukemia. Accessed 1 December 2022.https:\/\/www.jnj.com\/new\u2010data\u2010from\u2010phase\u20103\u2010glow\u2010study\u2010show\u2010fixed\u2010duration\u2010treatment\u2010with\u2010imbruvica\u2010ibrutinib\u2010plus\u2010venetoclax\u2010demonstrated\u2010deeper\u2010and\u2010sustained\u2010undetectable\u2010minimal\u2010residual\u2010disease\u2010outcomes\u2010in\u2010first\u2010line\u2010chronic\u2010lymphocytic\u2010leukemia"},{"key":"e_1_2_10_19_1","unstructured":"Johnson & Johnson.New results from the phase 3 GLOW study of fixed\u2010duration treatment with IMBRUVICA\u00ae (ibrutinib) plus venetoclax demonstrate robust efficacy and sustained response in older unfit patients with previously untreated chronic lymphocytic leukemia. Accessed 7 February 2023.https:\/\/www.jnj.com\/new\u2010results\u2010from\u2010the\u2010phase\u20103\u2010glow\u2010study\u2010of\u2010fixed\u2010duration\u2010treatment\u2010with\u2010imbruvica\u2010ibrutinib\u2010plus\u2010venetoclax\u2010demonstrate\u2010robust\u2010efficacy\u2010and\u2010sustained\u2010response\u2010in\u2010older\u2010unfit\u2010patients\u2010with\u2010previously\u2010untreated\u2010chronic\u2010lymphocytic\u2010leukemia"},{"key":"e_1_2_10_20_1","unstructured":"KaterA OwenC MorenoC et al.Fixed\u2010duration ibrutinib and venetoclax (I+V) versus chlorambucil plus obinutuzumab (CLB+O) for first\u2010line (1L) chronic lymphocytic leukemia (CLL): primary analysis of the phase 3 GLOW study. Oral presented at European Hematology Association (EHA) Virtual Congress; 9\u201312 June 2021: LB1902."},{"key":"e_1_2_10_21_1","unstructured":"NiemannC MunirT MorenoC et al.Residual disease kinetics among patients with high\u2010risk factors treated with first\u2010line fixed\u2010duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O): the GLOW study. Oral Presentation Presented at American Society of Hematology (ASH) Annual Meeting & Exposition San Diego CA USA; 10\u201313 December 2022: 93."},{"key":"e_1_2_10_22_1","doi-asserted-by":"crossref","unstructured":"MorenoC MunirT OwenC et al.First\u2010line fixed\u2010duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O): up to 5\u2009years' follow\u2010up from the GLOW study. Oral Presented at American Society of Hematology (ASH) Annual Meeting; 9\u201312 December 2023 San Francisco USA: 634.","DOI":"10.1182\/blood-2023-177713"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S1458"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.187583"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.0779"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000491382"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s44228-022-00015-5"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280376"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182907"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2018.1449616"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-020-05560-4"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3770-0"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01054-w"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T06:35:58Z","timestamp":1714113358000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,11]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/ejh.14186"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14186","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,11]]},"assertion":[{"value":"2023-10-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}